Mode
Text Size
Log in / Sign up
N/A Completed N=8 Treatment

Motivation Skills Training for Schizophrenia

Source: ClinicalTrials.gov NCT05746455 ↗
Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcomePrimary: Change in Motivation and Pleasure Scale (MAP) — 0.50 score on a scale

Summary

This study will take place at one outpatient clinic serving adults with serious mental illness and will recruit ten individuals (N=10) with a DSM-5 diagnosis of schizophrenia or schizoaffective disorder to participate in an Open Trial of Motivation Skills Training (MST). MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior. Participants who consent for research will complete assessments of motivation, goal attainment, quality of life, executive functioning, community functioning, and psychiatric symptoms severity. The intervention phase will be approximately 12 weeks in duration and will entail weekly MST group sessions. At treatment endpoint, participants will be asked to repeat the assessment battery from baseline as well as a satisfaction survey. Change in motivation, goal attainment and quality of life will indicate whether MST is engaging the hypothesized target (motivation) and whether there is impact on functioning.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Motivation and Pleasure Scale (MAP)
0.50
PRIMARY
Change in Goal Attainment Scaling (GAS)
2.0
SECONDARY
Change in Heinrichs Carpenter Quality of Life Scale (QLS)
5.17

Eligibility Criteria

Inclusion Criteria

  • Age 18-65
  • A primary Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of schizophrenia or schizoaffective disorder
  • Medically and psychiatrically stable outpatient status
  • English Fluency

Exclusion Criteria

  • Indications of Intellectual Disability as documented in medical history or measured by < 70 premorbid full scale Intelligence Quotient (IQ) estimate
  • Severe substance use within the past 3 months determined by DSM-5 criteria
  • Neurologic condition causing brain disease
  • Mild to severe cognitive impairment associated with possible dementia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05746455). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search